Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

(2014) Rosario Pivonello et al.   CLINICAL ENDOCRINOLOGY

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects

(2012) R A Feelders et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabergoline monotherapy in the long-term treatment of Cushing's disease

(2010) Ariane Godbout et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Cushing's Syndrome

(2008) Rosario Pivonello et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement

(2008) B. M. K. Biller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery

(2008) Rosario Pivonello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM